On Thursday, Stifel, a financial services firm, revised its price target for eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a clinical-stage biopharmaceutical company. The firm lowered the price target to $10.00 from the previous $21.00 while maintaining a Buy rating on the stock. The adjustment follows the unsuccessful outcome of the KICKSTART trial of tomivosertib for non-small cell lung cancer (NSCLC), leading to its removal from the firm's financial model.
The management of eFFECTOR Therapeutics has decided to discontinue the tomivosertib program after it failed to meet the pre-specified hazard ratio (HR) in the trial. The progress-free survival (PFS) and overall survival (OS) curves were determined not to justify further capital investment into the project. This development has resulted in a significant drop in the company's stock price, which Stifel suggests reflects a lack of enthusiasm for another of eFFECTOR's drugs, zotatifin, which is being developed for ER+ Breast Cancer.
Stifel's analysis indicates that the competitive landscape in breast cancer treatment and early-stage data for zotatifin, coupled with balance sheet concerns, have contributed to the cautious investor sentiment. Despite these challenges, Stifel remains positive on the potential of zotatifin. To account for the increased financial risk, the firm has raised its discount rate to 14%.
Looking ahead, Stifel anticipates that additional data on zotatifin, expected in the second half of 2024, could potentially improve market sentiment towards eFFECTOR Therapeutics. The firm's stance remains optimistic regarding the future prospects of zotatifin, despite the recent setback with the KICKSTART trial and the subsequent impact on the company's financial outlook.
InvestingPro Insights
As investors recalibrate their expectations for eFFECTOR Therapeutics following the KICKSTART trial outcome, real-time data from InvestingPro offers a deeper look into the company's financial health and market performance. The market capitalization of eFFECTOR Therapeutics stands at a modest $11.63 million, reflecting the market's current valuation of the company post-trial results. Despite the setback, the company has experienced a significant return over the past week, with a 14.45% price total return, hinting at some recovery in investor confidence.
However, InvestingPro Tips highlight several concerns that investors should be aware of. The company is quickly burning through cash and has weak gross profit margins, with the last twelve months as of Q4 2023 showing a gross profit of -$22.92 million. Additionally, eFFECTOR's short term obligations exceed its liquid assets, which could pose liquidity risks. Analysts are not optimistic about the company's profitability in the near future, as eFFECTOR is not expected to be profitable this year. Despite these challenges, the company has seen a high return over the last year, with a 77.29% price total return, demonstrating some levels of investor optimism in the longer term.
For those considering an investment in eFFECTOR Therapeutics, it's worth noting that the company operates with a moderate level of debt and does not pay a dividend to shareholders. For a comprehensive set of additional InvestingPro Tips, interested investors can visit https://www.investing.com/pro/EFTR. Moreover, by using the coupon code PRONEWS24, investors can receive an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking even more insights to guide their investment decisions. There are 9 more InvestingPro Tips available for eFFECTOR Therapeutics that could provide valuable context and foresight into the company's financial trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.